Andrew S. Ittleman/LinkedIn
Nov 5, 2025, 05:27
Andrew S. Ittleman: Florida’s New Stem Cell Laws Raise FDA and Patient Safety Concerns
Andrew S. Ittleman, Owner at Fuerst Ittleman David & Joseph, shared on LinkedIn:
”In July, Florida passed new “stem cell therapy” laws, which allow physicians to administer allogeneic “stem cell” products to patients. Among other problems with Florida’s new stem cell laws, they (i) authorize products which FDA prohibits, (ii) do not define “stem cell,” (iii) create a risk of patient confusion.
We have decades of history to understand the potential consequences of these laws, but that history seems to have been ignored during the legislative process. I explore these issues in the article available at the link below.”
Find more information here.
Stay informed with Hemostasis Today.
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC
-
Feb 23, 2026, 12:25Ryan Williams: Excellent Highlights on The Heterogeneity of PRP Preparation
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
-
Feb 23, 2026, 12:02Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial
-
Feb 23, 2026, 11:37Charles Okyere Boadu: Blood Donation Helps Lower Your Risk of Stroke and Organ Damage